JP5667067B2 - 抗ｔｇｆベータ受容体ｉｉ抗体 - Google Patents

抗ｔｇｆベータ受容体ｉｉ抗体 Download PDF

Info

Publication number
JP5667067B2
JP5667067B2 JP2011534731A JP2011534731A JP5667067B2 JP 5667067 B2 JP5667067 B2 JP 5667067B2 JP 2011534731 A JP2011534731 A JP 2011534731A JP 2011534731 A JP2011534731 A JP 2011534731A JP 5667067 B2 JP5667067 B2 JP 5667067B2
Authority
JP
Japan
Prior art keywords
antibody
seq
tgfβrii
sequence
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011534731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508170A (ja
JP2012508170A5 (ru
Inventor
ヤン・ウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone LLC filed Critical ImClone LLC
Publication of JP2012508170A publication Critical patent/JP2012508170A/ja
Publication of JP2012508170A5 publication Critical patent/JP2012508170A5/ja
Application granted granted Critical
Publication of JP5667067B2 publication Critical patent/JP5667067B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011534731A 2008-11-07 2009-10-29 抗ｔｇｆベータ受容体ｉｉ抗体 Expired - Fee Related JP5667067B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19869708P 2008-11-07 2008-11-07
US61/198,697 2008-11-07
US17036909P 2009-04-17 2009-04-17
US61/170,369 2009-04-17
PCT/US2009/062450 WO2010053814A1 (en) 2008-11-07 2009-10-29 Anti-tgf-beta receptor ii antibodies

Publications (3)

Publication Number Publication Date
JP2012508170A JP2012508170A (ja) 2012-04-05
JP2012508170A5 JP2012508170A5 (ru) 2014-04-24
JP5667067B2 true JP5667067B2 (ja) 2015-02-12

Family

ID=41508691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534731A Expired - Fee Related JP5667067B2 (ja) 2008-11-07 2009-10-29 抗ｔｇｆベータ受容体ｉｉ抗体

Country Status (19)

Country Link
US (2) US8147834B2 (ru)
EP (1) EP2356152A1 (ru)
JP (1) JP5667067B2 (ru)
KR (1) KR101283856B1 (ru)
CN (1) CN102209727B (ru)
AR (1) AR073909A1 (ru)
AU (1) AU2009311375B2 (ru)
BR (1) BRPI0921263A2 (ru)
CA (1) CA2742961C (ru)
EA (1) EA025169B1 (ru)
IL (1) IL211842A (ru)
JO (1) JO3096B1 (ru)
MX (1) MX2011004871A (ru)
NZ (1) NZ591943A (ru)
PA (1) PA8846101A1 (ru)
SG (1) SG10201401280TA (ru)
TW (1) TWI384998B (ru)
WO (1) WO2010053814A1 (ru)
ZA (1) ZA201103178B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140982A1 (es) * 2011-01-06 2014-08-22 Glaxo Group Ltd Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
EP4223873A3 (en) 2015-01-31 2023-09-06 The Trustees of the University of Pennsylvania Compositions and methods for t cell delivery of therapeutic molecules
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
TW201825519A (zh) 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
CN106884005A (zh) * 2017-01-19 2017-06-23 樊克兴 一种结直肠癌抗原特异性t细胞的制备方法
EP3700568A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
EP3700540A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS OF DEPRODUCTION FROM CD117 + CELLS
CN107973853B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备Smad2蛋白特异性抗体的方法及其应用
CN116375869A (zh) 2019-12-24 2023-07-04 美勒斯公司 TGF-β-RII结合蛋白质
KR102314157B1 (ko) * 2020-01-10 2021-10-19 주식회사 뉴클릭스바이오 TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
WO2023198194A1 (en) * 2022-04-15 2023-10-19 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-cd40 antibodies and uses thereof
CN116178567A (zh) * 2022-10-28 2023-05-30 四川大学华西医院 一种靶向TGFβRII的嵌合抗原受体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DE69232986T2 (de) * 1991-10-31 2003-12-11 Whitehead Biomedical Inst TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
JP2004121001A (ja) * 2002-08-07 2004-04-22 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体
US20090186076A1 (en) * 2006-02-01 2009-07-23 Kazunori Kataoka Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent

Also Published As

Publication number Publication date
KR101283856B1 (ko) 2013-07-15
EA025169B1 (ru) 2016-11-30
MX2011004871A (es) 2011-07-13
NZ591943A (en) 2012-11-30
JO3096B1 (ar) 2017-03-15
ZA201103178B (en) 2012-10-31
JP2012508170A (ja) 2012-04-05
AU2009311375A1 (en) 2010-05-14
CA2742961A1 (en) 2010-05-14
AR073909A1 (es) 2010-12-09
US20100119516A1 (en) 2010-05-13
US8147834B2 (en) 2012-04-03
EP2356152A1 (en) 2011-08-17
IL211842A0 (en) 2011-06-30
WO2010053814A1 (en) 2010-05-14
IL211842A (en) 2016-09-29
TWI384998B (zh) 2013-02-11
KR20110067155A (ko) 2011-06-21
AU2009311375B2 (en) 2014-07-31
CN102209727A (zh) 2011-10-05
BRPI0921263A2 (pt) 2015-08-04
US20120177666A1 (en) 2012-07-12
CA2742961C (en) 2016-08-30
EA201170659A1 (ru) 2011-10-31
CN102209727B (zh) 2014-07-30
SG10201401280TA (en) 2014-05-29
TW201026326A (en) 2010-07-16
PA8846101A1 (es) 2010-06-28

Similar Documents

Publication Publication Date Title
JP5667067B2 (ja) 抗ｔｇｆベータ受容体ｉｉ抗体
JP2012508170A5 (ru)
JP2021508676A (ja) 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用
JP4864900B2 (ja) 血管内皮成長因子受容体−ｉに対する抗体
JP7273110B2 (ja) 高親和性抗ｖｅｇｆ抗体
CN105829345B (zh) 结合egfr和met的多功能抗体
WO2020168555A1 (zh) Cd3抗原结合片段及其应用
JP6925981B2 (ja) Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体
WO2022068810A1 (zh) 抗Claudin18.2和CD3的双特异性抗体以及其用途
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
KR20220082007A (ko) 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
TWI413527B (zh) 抗ｖｅｇｆｒ－３抗體組合物
CN114786722A (zh) 抗类趋化因子受体1人源化抗体及其治疗应用
WO2022237819A1 (zh) 抗Siglec-15抗体及其用途
TW202334228A (zh) B7h6抗體及其應用
EP3777889A1 (en) Use of probdnf regulator in b cell-related diseases
CA2762446C (en) Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis
JP2021521804A (ja) 抗ｃｄ４０抗体およびその使用
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
TWI837517B (zh) 抗claudin 18.2和cd3的雙特異性抗體以及其用途
JP2018505144A (ja) 抗ｃｘｃｌ１２抗体分子およびその使用
KR20240022546A (ko) 항il-36r 항체 및 그의 사용
CA3230246A1 (en) Bispecific antibody and use thereof

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20121022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121022

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140703

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141211

R150 Certificate of patent or registration of utility model

Ref document number: 5667067

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees